

# Association of Histo–Blood Group Antigens and Susceptibility to Norovirus Infections

Barry H. G. Rockx,<sup>1</sup> Harry Vennema,<sup>1</sup> Christian J. P. A. Hoebe,<sup>2</sup> Erwin Duizer,<sup>1</sup> and Marion P. G. Koopmans<sup>1</sup>

<sup>1</sup>Diagnostic Laboratory for Infectious Diseases and Perinatal Screening, National Institute for Public Health and the Environment, Bilthoven, and <sup>2</sup>Department of Infectious Diseases, Western and Eastern South Limburg Municipal Health Service, Heerlen, The Netherlands

**Background.** Noroviruses (NoVs) are the leading cause of viral gastroenteritis in humans of all ages. Challenge studies that used the NoV prototype strain Norwalk virus (NV) have shown that some individuals are not susceptible to infection, suggesting the absence of a receptor. Recent studies have identified histo–blood group antigens (HBGAs) as possible receptors. Being a nonsecretor and presence of HBGA type B were associated with protection against infection with NV, a genogroup (GG) I NoV.

**Methods.** In the present retrospective study, we investigated the association between presence of HBGAs and the risk of infection with another NoV belonging to GGI (Hu/NV/I/Birmingham/93/UK). The study was done as part of an investigation of a waterborne outbreak in a group of schoolchildren and of a cohort of healthy adults. The ABH histo–blood group phenotype was determined by use of saliva or serum samples from these individuals.

**Results.** Presence of HBGA type B was significantly correlated with a lack of susceptibility to infection with GGI NoV and with an absence of antibodies. No correlation was found with GGII NoV. Although the infection rate in nonsecretors was lower, this difference was not statistically significant and several children lacking HBGAs in saliva were found to be infected.

**Conclusions.** Individuals with the HBGA type B may be protected against infection with GGI (but not GGII) NoVs. The association between susceptibility to NoV infection and being a secretor may be restricted to GGI NoV.

In recent years, Noroviruses (NoVs) have emerged as a leading cause of viral gastroenteritis in humans of all ages. They are transmitted by the fecal–oral route, either indirectly (by exposure to contaminated food or water) or directly (by person-to-person contact). The NoVs are genetically diverse, with >15 genotypes distributed over 3 genogroups (GGI, GGII, and GGIII) [1].

Several volunteer challenge studies of NoVs that used the prototype strain Norwalk virus (NV; 8FIIb) have shown that some individuals remain uninfected even when challenged with high or multiple doses [2–4]. Evidence of protective immunity to NoV infection is controversial; short-term immunity has been observed

[3–5], but antibodies do not seem to confer protection against NoV infection [6].

Also, despite the high prevalence of antibodies in the population, NoV infection causes disease in people of all ages. The absence of antibodies to NV (GGI.1) in a group of infection-resistant volunteers suggested genetic nonsusceptibility to NV (e.g., through the absence of a receptor [3, 6, 7], which, so far, has remained elusive). However, recent studies have shown that recombinant NoV viruslike particles (VLPs) from different genogroups (GGI and GGII) display different binding patterns to histo–blood group antigens (HBGAs) present in saliva and expressed on red blood cells (RBCs) and gastroduodenal epithelial cells [8–12]. These antigens are widely distributed in human tissues [13, 14] and represent the terminal part of an oligosaccharide chain linked to proteins or lipids.

The HBGA determinants are carried on 4 main types of precursor saccharide structures. Two enzymes ( $\alpha$ 1,2-fucosyltransferases [FUT1 and FUT2]) are responsible for synthesis of H antigen from the precursor chain by addition of a fucose group. The H antigen then serves as the substrate for A and B glycosyltransferases, which

Received 11 June 2004; accepted 1 September 2004; electronically published 25 January 2005.

Financial support: Zorgonderzoek Nederland, Medische Wetenschappen (grant 2100.0043).

Reprints or correspondence: Dr. Marion P. G. Koopmans, Diagnostic Laboratory for Infectious Diseases and Perinatal Screening, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands (marion.koopmans@rivm.nl).

The Journal of Infectious Diseases 2005;191:749–54

© 2005 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2005/19105-0016\$15.00

add the A or B epitopes that determine the ABO histo–blood group phenotype. FUT1 preferentially acts on type 2 chains, whereas FUT2 preferentially acts on type 1, 2, and 3 precursor saccharides. Differential expression patterns have been observed for FUT1 and FUT2 in different tissues [14–16]. For example, on the surface epithelial cells of gastroduodenal tissues, the expression of H type 1 HBGA is under the control of the FUT2 gene. Several inactivating mutations have been identified in the FUT2 gene, which result in the absence of HBGAs in secretions from ~20% of white individuals (termed “nonsecretors”) [14, 17, 18]. The H type 1 HBGA was identified as the main ligand for binding of recombinant NV (rNV) VLPs to gastroduodenal epithelial cells [12] and was, therefore, considered as a possible NoV receptor. Nonsecretors lack the H type 1 HBGA on gastroduodenal epithelial cells, which may explain their nonsusceptibility to NV infection [14].

In addition to the binding to H type 1 HBGA, an association between ABO histo–blood group phenotype and risk of NoV infection and disease has been demonstrated [19, 20]. Presence of HBGA type B was associated with protection against symptomatic NV infection [20]. Similarly, presence of HBGA type A on the subjacent H antigen diminished rNV VLP binding [12]. These observations suggest that presence of an HBGA interferes with the binding of NoV to the H antigen, possibly by partial blocking of the binding site.

The association found with HBGA-ABH has been observed *in vitro* for several genotypes of NoV. *In vivo* data on the association between presence of HBGAs, being a secretor, and susceptibility to infection with NoV genotypes other than NV are limited [19].

In the present retrospective study, we investigated whether the association between presence of HBGAs, being a secretor, and susceptibility to NV infection is specific to the NV genotype or whether it can be generalized to other NoV genotypes within the same or more distantly related genogroups. We studied the association between presence of HBGA-ABH and infection with another GGI virus (Hu/NV/I/Birmingham/93/UK) after natural infection in a common-source waterborne outbreak [21]. The Hu/NV/I/Birmingham/93/UK lineage has been described elsewhere [22] and has caused sporadic outbreaks since it was first described. It clusters within GGI and exhibits 64.3% amino acid identity with NV in the capsid protein. Also, the association between presence of NoV-specific antibodies, as a measure of infection history, and the ABO histo–blood group phenotype was studied in a cohort of healthy adults.

## SUBJECTS, MATERIALS, AND METHODS

**Study samples from persons involved in an outbreak.** In June 2002, an outbreak of gastroenteritis occurred in a group of primary schoolchildren after a field trip to a recreation ground [21]. Stool samples from these children were obtained and used

for detection and typing of virus. Information on clinical symptoms and exposure was obtained through questionnaires. Infection was defined as the presence of virus in stool samples and/or the presence of clinical symptoms (diarrhea or vomiting). A recreational water fountain was found to be the source of the Hu/NV/I/Birmingham/93/UK, which was detected in both water samples and materials from patients. Saliva samples were obtained from children who had played in the fountain and were typed for presence of ABH antigens in relation to histo–blood group phenotype and secretor status.

**Study samples from a cohort of healthy adults.** Detailed information about the cohort will be given elsewhere [23]; it included 212 veterinarians who attended an annual practitioners’ association meeting in The Netherlands. Ages ranged from 20 to >50 years (20–29 years,  $n = 19$ ; 30–39 years,  $n = 53$ ; 40–49 years,  $n = 76$ ; and >50 years,  $n = 62$ ), with 80% men and 20% women. Five-milliliter blood samples were collected from these individuals by venipuncture, refrigerated (4°C), and transported to the laboratory, where the serum was separated, heat-inactivated for 30 min at 56°C, and frozen at –20°C within 24 h of collection. Informed consent was obtained from all participants in the present study.

**Secretor status phenotyping.** The secretor status of the exposed children was determined by testing for presence of H antigen in saliva samples by use of a microplate hemagglutination (HA) inhibition (HI) assay [24]. A total of 50  $\mu$ L of anti-H lectin was serially diluted (2-fold) in saliva (diluted 1:64 in PBS); 50  $\mu$ L of a 0.5% RBC solution in saline (blood group type O<sup>–</sup>; CLB) was added and incubated for 30 min at room temperature. If present in saliva (in secretors), the H antigen will inhibit HA of O<sup>–</sup> RBCs by anti-H lectin. A saliva sample from a known secretor and saline were included as positive and negative controls, respectively. An HI assay result was considered to be positive when the HA titer was reduced by >2-fold, compared with the HA titer for the saline control. A positive HI assay result indicated that soluble H antigen was present in the saliva (secretor).

**ABO histo–blood group phenotyping.** The ABO histo–blood group phenotype of secretors was determined by use of a microplate HI assay with saliva samples. A total of 50  $\mu$ L of anti-A and anti-B monoclonal antibodies (CLB) was serially diluted (2-fold) in saliva (diluted 1:64 in PBS); 50  $\mu$ L of a 0.5% RBC solution in saline (blood group type A<sub>1</sub> or B; CLB) was added and incubated for 30 min at room temperature. Saliva samples with known A, B, or O phenotype and saline were tested in parallel as positive and negative controls, respectively. An HI assay result was considered to be positive, indicating presence of type A and B HBGAs in the saliva, when the HA titer was reduced by >2-fold, compared with the HA titer for the saline control. The HI assay was validated by determining the histo–blood group phenotype of saliva samples from 10

**Table 1. Association between secretor status and outcome of exposure to Hu/NV/I/Birmingham/93/UK.**

Secretor status	Outcome of exposure		Overall
	Infected	Not infected	
Secretor	20 (83)	2 (40)	22 (76)
Nonsecretor	4 (17)	3 (60) <sup>a</sup>	7 (24)

**NOTE.** Data are no. (%) of individuals.

<sup>a</sup> Odds ratio, 0.133 (95% confidence interval, 0.019–0.938).

*P* = .075, Fisher's exact test.

individuals with known histo–blood group phenotypes, as determined by serum phenotyping, which is described below. No discrepancies were observed. ABO histo–blood group phenotyping of serum from the healthy adult cohort was done by adding 50  $\mu$ L of serum to an equal volume of a 0.5% RBC solution (blood group type A<sub>1</sub>, B, or O<sup>−</sup>; CLB), incubating for 30 min at room temperature, and testing for HA.

**Detection of NoV-specific antibodies by ELISA.** Serum samples were tested for IgG antibodies to NV (Hu/NV/I/Norwalk/1968/US) and Lordsdale virus (LV; Hu/NV/II/Bristol/1993/UK) by use of direct EIA with recombinant capsid antigens (provided by X. Jiang, Cincinnati Children's Hospital, and I. Clarke, Southampton General Hospital, respectively). Both rNV and recombinant LV capsid proteins were produced in a baculovirus expression system, as described elsewhere [25, 26]. Optimal working dilutions were determined by serial dilution of the antigens, as follows. Microtiter plates were coated overnight at 4°C with purified recombinant capsid proteins in PBS (50  $\mu$ L/well); after 3 rinses with 0.05% Tween 20–PBS, the wells were blocked with 5% Blotto (Pierce) in PBS, for 1 h at 37°C. The wells were then washed and incubated for 90 min at 37°C with a 1:100 dilution of serum samples in 1% Blotto in PBS (50  $\mu$ L/well). After washing, 50  $\mu$ L of a 1:1000 dilution (in 1% Blotto in PBS) of alkaline phosphatase-conjugated goat anti-human IgG (Sigma-Aldrich) was added to the wells, followed by incubation for 90 min at 37°C. After washing, 50  $\mu$ L of p-nitrophenylphosphate substrate (Sigma-Aldrich) was added to the wells, to a concentration of 1 mg/mL in 0.1 mol/L glycine buffer (pH 10.4), for 30 min at room temperature. The absorption values were measured at 405 nm by use of an ELISA reader (Organon Teknika). Two positive and 2 negative control serum samples were included on every plate.

Previous testing of negative control wells coated with equivalent concentrations of wild-type baculovirus (AcNPV)-infected SF 9 antigen and 120 human serum samples showed no difference in absorption values with PBS; therefore, wells without VLP coating were included as negative controls. A sample was considered to be positive when the net absorbance (optical density [OD]) was greater than the set cutoff (mean + 3 SD of the OD of negative control serum samples).

**Statistical analysis.** Odds ratios (ORs) and 95% confidence

intervals (CIs) were calculated for blood group and secretor status. HBGA data were analyzed by use of Fisher's exact test (2-tailed).

## RESULTS

**Waterborne outbreak.** A group of 231 children visited an interactive recreational water fountain. Information on clinical symptoms and presence of virus in stool samples was available for 29 children exposed to virus by playing in the water fountain, and saliva samples were collected from all of the children. Of the 24 children in whom NoV infection was diagnosed, 20 (84%) received the diagnosis on the basis of detection of virus in stool samples, whereas the remaining 4 children received the diagnosis on the basis of clinical symptoms.

**Association of secretor status and outcome of infection.** No H antigen was detected in the saliva samples from 7 (24%) of 29 children. Clinical symptoms combined with presence of virus in stool samples confirmed infection in both secretors (*n* = 20) and nonsecretors (*n* = 4) (table 1). All 4 infected nonsecretors received a diagnosis of NoV infection on the basis of detection of virus in stool samples. Although not significant there was a trend showing that nonsecretors were less likely to become infected with Hu/NV/I/Birmingham/93/UK (OR, 0.13 [95% CI, 0.02–0.94]; *P* = .075, Fisher's exact test).

**Association of blood group distribution and outcome of infection.** The histo–blood group phenotype could be determined by use of saliva samples from the 22 children secreting HBGA-ABH. The overall blood group distribution was comparable to the reference frequency in individuals from western Europe (table 2). Presence of HBGA type B was significantly correlated with protection against infection (*P* = .004, Fisher's exact test) (table 2).


**Association of blood group distribution and presence of NoV-specific antibodies.** A total of 212 serum samples from a cohort of healthy adults were phenotyped for ABO histo–blood group. Overall, a normal frequency distribution of ABO histo–blood group phenotypes was observed, compared with the reference frequency distribution in individuals from western Europe (figure 1). No difference in frequency distribution was

**Table 2. Distribution of histo–blood group antigens (HBGAs) by outcome of exposure to Hu/NV/I/Birmingham/93/UK.**

HBGA type	Outcome of exposure		Overall
	Infected	Not infected	
A	9 (45)	0	9 (41)
B	0	2 (100) <sup>a</sup>	2 (10)
AB	0	0	0
O	11 (55)	0	11 (50)

**NOTE.** Data are no. (%) of individuals.

<sup>a</sup> *P* = .004, Fisher's exact test.



**Figure 1.** Distribution of ABO histo-blood group phenotypes among Norwalk virus (NV; genogroup I.1)-positive (NV<sup>+</sup>) and NV-negative (NV<sup>-</sup>) and Lordsdale virus (LV; genogroup II.4)-positive (LV<sup>+</sup>) and LV-negative (LV<sup>-</sup>) individuals, compared with that among a reference groups of western European individuals. Nos. of individuals are as follows: NV<sup>+</sup>,  $n = 171$ ; NV<sup>-</sup>,  $n = 41$ ; LV<sup>+</sup>,  $n = 168$ ; LV<sup>-</sup>,  $n = 44$ ; and overall,  $n = 212$ . The odds ratio (OR) for acquiring NV-specific IgG with histo-blood group antigen (HBGA) type A was 2.53 (95% confidence interval [CI], 1.19–5.42); the OR for acquiring NV-specific IgG with HBGA type B was 0.26 (95% CI, 0.10–0.66).

observed for LV-positive and LV-negative serum samples or for NV-positive serum samples. However, the frequency distribution of NV-negative serum samples was different, with an increased number of HBGA type B–positive serum samples. Individuals with HBGA type B were significantly less likely to acquire NV-specific IgG (OR, 0.26 [95% CI, 0.10–0.66];  $P = .0098$ , Fisher’s exact test). In addition, individuals with HBGA type A were significantly more likely to acquire NV-specific IgG (OR, 2.53 [95% CI, 1.19–5.42];  $P = .021$ , Fisher’s exact test).

## DISCUSSION

In the present retrospective study, the association between NoV infection and presence of HBGAs was investigated in a group of schoolchildren involved in a waterborne outbreak and in a cohort of healthy adults. In addition, the association between secretor status and susceptibility to Hu/NV/I/Birmingham/93/UK infection was investigated. We have shown that presence of HBGA type B is associated with a lack of susceptibility to Hu/NV/I/Birmingham/93/UK (GGI.3) infection. In addition, presence of HBGA type B was associated with an absence of antibodies against NV (GGI.1) but not against LV (GGII.4).

Recent studies of volunteers have shown a correlation between susceptibility to NV infection, the prototype GGI virus, and presence of antigens of the ABH histo-blood group system [8]. Harrington et al. speculated whether the associations between ABH phenotype and NV infection could be generalized to other NoV lineages and concluded that additional volunteer challenge studies with other NoV strains are needed.

A trend of association between being a secretor and susceptibility to Hu/NV/I/Birmingham/93/UK infection was found,

although 4 individuals with a nonsecretor phenotype became infected. This finding suggests that protection from infection in nonsecretors, reported elsewhere for this genogroup [27], may not be complete and that other receptors, possibly H type 3 or 4 (which are expressed independent of the status of being a secretor [28]), are likely to be involved. However, secretor status was determined by phenotyping of saliva samples, which is not as sensitive as genotyping, and the concentration of H antigen in saliva may have been below the limit of detection. Unfortunately, no materials were available for confirmation of secretor status by genotyping [29]. Interestingly, in agreement with the observations of decreased susceptibility to NV infection in individuals with HBGA type B [20], none of the individuals with HBGA type B became infected after exposure to the Hu/NV/I/Birmingham/93/UK strain. Although this finding is based on only 2 observations, it suggests that presence of HBGA type B may interfere with attachment of virus and be a more common property of GGI viruses [8, 20, 27].

Two limitations of the present study are acknowledged. First, diagnosis of NoV infection was not based entirely on the detection of virus in stool samples but also included, for 16% of individuals, diagnosis based on the presence of clinical signs. Although asymptomatic infections do occur in a small number of cases [30] and although we previously found that virus shedding can be missed by testing too early [31], the chance that both occurred at the same time in 1 individual is very low and, therefore, unlikely to have had a significant effect on the present study. Second, even though a response rate of only 13% is low and a selection bias may therefore have occurred for both secretor status and histo-blood group phenotype, the percentage of nonsecretors represented in the present study (24%) is in agreement with the distribution of nonsecretors in the general population (20%). Also, the overall histo-blood group distribution is not significantly different from the distribution in the general population. This suggests that the low response rate did not induce a selection bias.

To investigate whether this association is true for other NoV strains, the association between antibodies and HBGAs was studied. Presence of specific antibodies indicates that an individual had been infected by that (or a related) virus in the past and is therefore susceptible to that strain. Several studies have shown significant cross-reactivity between different NoV strains, and this cross-reactivity was mainly restricted to NoV strains within a genogroup [32, 33]. By use of the current serological assays, no distinction can be made between antibodies directed against different NoV strains within a genogroup. Therefore, we assumed that presence of antibodies against NV (GGI) or LV (GGII) is indicative of previous infection with GGI or GGII NoV, respectively, and not necessarily the specific NoV type tested for. This assumption is further substantiated by the presence of antibodies directed against NV (GGI.1). The NV

strain has never been found in outbreaks or endemic infections; however, high seroprevalence against this virus has been found, suggesting that these antibodies are cross-reactive and were produced after infection with a related GGI virus. Since antibodies within a genogroup are cross-reactive, this observation may be true for several genotypes within the genogroup.

Individuals with HBGA type B were less likely to have antibodies against NV (GGI), suggesting that they are less susceptible to NV infection. That these same individuals were not less likely to have antibodies against GGII is in accordance with reports that LV (GGII) can bind to all HBGAs [10]. This difference may, in part, explain why GGI infections are less frequent than GGII infections [34].

Our data show that being a secretor is a correlate of protection against GGI NoV infection, although this is not the sole mechanism in nonsusceptibility. Our findings do support the concept of a decreased risk of infection by another GGI virus when HBGA type B is present, and this finding may be generalized for GGI (but not for GGII) viruses. Further research on the susceptibility and resistance to NoV infections should be conducted by the study of both volunteer challenge experiments and well-documented outbreaks of other NoV strains. It should be noted that future investigations of outbreaks that study the association between presence of HBGAs and susceptibility to infection should account for possible selection biases when multiple family members are involved in the outbreak, since secretor status and histo-blood group phenotype are genetically determined. In addition, both saliva and blood samples should be collected for determination of secretor status and for histo-blood group phenotyping and genotyping.

## Acknowledgments

We thank Erwin de Bruin and Bas van der Veer, for technical assistance, and M. C. Horzinek for critically reading the manuscript.

## References

1. Vinje J, Hamidjaja RA, Sobsey MD. Development and application of a capsid VP1 (region D) based reverse transcription PCR assay for genotyping of genogroup I and II Noroviruses. *J Virol Methods* **2004**; 116:109–17.
2. Gary GW, Anderson LJ, Keswick BH, et al. Norwalk virus antigen and antibody response in an adult volunteer study. *J Clin Microbiol* **1987**; 25:2001–3.
3. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. *N Engl J Med* **1977**; 297:86–9.
4. Wyatt RG, Dolin R, Blacklow NR, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. *J Infect Dis* **1974**; 129:709–14.
5. Dolin R, Blacklow NR, DuPont H, et al. Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. *Proc Soc Exp Biol Med* **1972**; 140:578–83.
6. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-

- challenge study of host susceptibility to Norwalk gastroenteritis in US adults. *J Infect Dis* **1990**; 161:18–21.
7. Graham DY, Jiang X, Tanaka T, Opekun AR, Madore HP, Estes MK. Norwalk virus infection of volunteers: new insights based on improved assays. *J Infect Dis* **1994**; 170:34–43.
8. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. *J Virol* **2002**; 76:12335–43.
9. Harrington PR, Vinje J, Moe CL, Baric RS. Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. *J Virol* **2004**; 78:3035–45.
10. Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. *J Infect Dis* **2003**; 188:19–31.
11. Hutson AM, Atmar RL, Marcus DM, Estes MK. Norwalk virus-like particle hemagglutination by binding to H histo-blood group antigens. *J Virol* **2003**; 77:405–15.
12. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. *Gastroenterology* **2002**; 122:1967–77.
13. Oriol R, Mollicone R, Coullin P, Dalix AM, Candelier JJ. Genetic regulation of the expression of ABH and Lewis antigens in tissues. *APMIS Suppl* **1992**; 27:28–38.
14. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. *APMIS* **2000**; 108:1–28.
15. D'Adamo PJ, Kelly GS. Metabolic and immunologic consequences of ABH secretor and Lewis subtype status. *Altern Med Rev* **2001**; 6:390–405.
16. Morgan WT, Watkins WM. Unravelling the biochemical basis of blood group ABO and Lewis antigenic specificity. *Glycoconj J* **2000**; 17:501–30.
17. Henry SM. Molecular diversity in the biosynthesis of GI tract glycoconjugates: a blood-group-related chart of microorganism receptors. *Transfus Clin Biol* **2001**; 8:226–30.
18. Kelly RJ, Ernst LK, Larsen RD, Bryant JG, Robinson JS, Lowe JB. Molecular basis for H blood group deficiency in Bombay (Oh) and para-Bombay individuals. *Proc Natl Acad Sci USA* **1994**; 91:5843–7.
19. Hennessy EP, Green AD, Connor MP, Darby R, MacDonald P. Norwalk virus infection and disease is associated with ABO histo-blood group type. *J Infect Dis* **2003**; 188:176–7.
20. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. *J Infect Dis* **2002**; 185:1335–7.
21. Hoebe CJ, Vennema H, Husman AM, van Duynhoven YT. Norovirus outbreak among primary schoolchildren who had played in a recreational water fountain. *J Infect Dis* **2004**; 189:699–705.
22. Green J, Vinje J, Gallimore CI, Koopmans M, Hale A, Brown DW. Capsid protein diversity among Norwalk-like viruses. *Virus Genes* **2000**; 20:227–36.
23. Widdowson M, Rockx B, Schepp R, Vinje J, van Duynhoven Y, Koopmans M. Detection of serum antibodies to bovine Norovirus in veterinarians and the general population in The Netherlands. *J Med Virol* (in press).
24. Mallory DA, ed. *Immunohematology methods and procedures*. Rockville: American National Red Cross, **1993**.
25. Dingle KE, Lambden PR, Caul EO, Clarke IN. Human enteric *Caliciviridae*: the complete genome sequence and expression of virus-like particles from a genetic group II small round structured virus. *J Gen Virol* **1995**; 76:2349–55.
26. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. *J Virol* **1992**; 66:6527–32.
27. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. *Nat Med* **2003**; 9:548–53.
28. Clausen H, Holmes E, Hakomori S. Novel blood group H glycolipid antigens exclusively expressed in blood group A and AB erythrocytes (type 3 chain H). II. Differential conversion of different H substrates

- by A1 and A2 enzymes, and type 3 chain H expression in relation to secretor status. *J Biol Chem* **1986**; 261:1388–92.
29. Svensson L, Petersson A, Henry SM. Secretor genotyping for A385T, G428A, C571T, C628T, 685delTGG, G849A, and other mutations from a single PCR. *Transfusion* **2000**; 40:856–60.
  30. de Wit MA, Koopmans MP, Kortbeek LM, et al. Sensor, a population-based cohort study on gastroenteritis in The Netherlands: incidence and etiology. *Am J Epidemiol* **2001**; 154:666–74.
  31. Rockx B, De Wit M, Vennema H, et al. Natural history of human calicivirus infection: a prospective cohort study. *Clin Infect Dis* **2002**; 35: 246–53.
  32. Farkas T, Thornton SA, Wilton N, Zhong W, Altaye M, Jiang X. Homologous versus heterologous immune responses to Norwalk-like viruses among crew members after acute gastroenteritis outbreaks on 2 US Navy vessels. *J Infect Dis* **2003**; 187:187–93.
  33. Noel JS, Ando T, Leite JP, et al. Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. *J Med Virol* **1997**; 53:372–83.
  34. Lopman BA, Brown DW, Koopmans M. Human caliciviruses in Europe. *J Clin Virol* **2002**; 24:137–60.